# Bexarotene

Bexarotene (Targretin, H.A.C. Pharma) has 1 EU-approved indication in 1 tumour type.

## Approved indications

### T-cell lymphoma

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| None | Monotherapy | 2nd line, advanced | Cutaneous T-cell lymphoma only; After at least one systemic treatment; Skin manifestations |

## Products

### Targretin

- Company: H.A.C. Pharma
- Target: Retinoid X receptor (RXR) agonist (rexinoid)
- Class: Retinoids for cancer treatment
- ATC: L01XF03
- EU approval: 29 Mar 2001
- Label revised: 12 Aug 2025
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/targretin-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/targretin-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/targretin

Mechanism (SmPC section 5.1): Bexarotene selectively binds and activates the three retinoid X receptors, which act as transcription factors regulating cell differentiation, proliferation and apoptosis. Its exact action in CTCL is unknown.

## Label wording

- **Bexarotene** (Targretin), T-cell lymphoma, 2nd line, advanced: “Targretin is indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) in adult patients refractory to at least one systemic treatment.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/targretin-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/bexarotene